Immuneering (IMRX) Competitors $4.18 +0.01 (+0.24%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$4.09 -0.09 (-2.15%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMRX vs. VALN, BCAX, PGEN, SIGA, ATYR, ORKA, CAPR, CGEM, MREO, and KMDAShould you be buying Immuneering stock or one of its competitors? The main competitors of Immuneering include Valneva (VALN), Bicara Therapeutics (BCAX), Precigen (PGEN), Siga Technologies (SIGA), aTyr Pharma (ATYR), Oruka Therapeutics (ORKA), Capricor Therapeutics (CAPR), Cullinan Therapeutics (CGEM), Mereo BioPharma Group (MREO), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Immuneering vs. Its Competitors Valneva Bicara Therapeutics Precigen Siga Technologies aTyr Pharma Oruka Therapeutics Capricor Therapeutics Cullinan Therapeutics Mereo BioPharma Group Kamada Immuneering (NASDAQ:IMRX) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations. Do insiders and institutionals have more ownership in IMRX or VALN? 67.7% of Immuneering shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 22.9% of Immuneering shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to IMRX or VALN? In the previous week, Valneva had 2 more articles in the media than Immuneering. MarketBeat recorded 5 mentions for Valneva and 3 mentions for Immuneering. Immuneering's average media sentiment score of 0.95 beat Valneva's score of 0.78 indicating that Immuneering is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend IMRX or VALN? Immuneering currently has a consensus target price of $13.25, suggesting a potential upside of 216.99%. Valneva has a consensus target price of $15.50, suggesting a potential upside of 140.31%. Given Immuneering's higher probable upside, equities analysts clearly believe Immuneering is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuneering 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, IMRX or VALN? Immuneering has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. Which has stronger valuation & earnings, IMRX or VALN? Valneva has higher revenue and earnings than Immuneering. Valneva is trading at a lower price-to-earnings ratio than Immuneering, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuneering$320K470.12-$61.04M-$1.96-2.13Valneva$183.52M2.99-$13.25M-$1.19-5.42 Is IMRX or VALN more profitable? Immuneering has a net margin of 0.00% compared to Valneva's net margin of -43.08%. Valneva's return on equity of -43.05% beat Immuneering's return on equity.Company Net Margins Return on Equity Return on Assets ImmuneeringN/A -119.22% -99.22% Valneva -43.08%-43.05%-16.23% SummaryImmuneering and Valneva tied by winning 8 of the 16 factors compared between the two stocks. Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRX vs. The Competition Export to ExcelMetricImmuneeringMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$150.06M$2.96B$5.61B$9.30BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-2.1320.2228.5219.58Price / Sales470.12290.74426.1793.37Price / CashN/A43.1536.0257.93Price / Book3.147.568.135.54Net Income-$61.04M-$55.11M$3.24B$257.73M7 Day Performance-6.07%3.81%0.20%-0.08%1 Month Performance76.37%11.60%5.98%8.09%1 Year Performance234.40%-2.11%26.15%13.02% Immuneering Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRXImmuneering3.3779 of 5 stars$4.18+0.2%$13.25+217.0%+242.6%$150.06M$320K-2.1360VALNValneva1.7972 of 5 stars$5.75-1.0%$15.50+169.6%-12.8%$494.40M$183.52M-4.83700Gap DownBCAXBicara TherapeuticsN/A$9.01-0.2%$31.86+253.6%N/A$492.46MN/A0.0032PGENPrecigen4.0457 of 5 stars$1.59-1.9%$6.00+277.4%+12.5%$478.19M$4.20M-2.84190News CoveragePositive NewsAnalyst RevisionSIGASiga Technologies2.2241 of 5 stars$6.73+0.6%N/A-26.6%$477.94M$138.72M10.0440News CoverageATYRaTyr Pharma2.0575 of 5 stars$5.30-0.2%$20.20+281.1%+219.0%$472.61M$230K-6.5453Gap DownHigh Trading VolumeORKAOruka Therapeutics2.9418 of 5 stars$13.29+5.5%$40.38+203.8%N/A$471.75MN/A-2.95N/ANews CoveragePositive NewsCAPRCapricor Therapeutics2.3695 of 5 stars$9.90-3.4%$32.22+225.5%+54.1%$468.19M$22.27M-6.97101Analyst ForecastCGEMCullinan Therapeutics1.7317 of 5 stars$7.42-5.0%$30.00+304.3%-55.1%$460.90MN/A-2.5530News CoverageMREOMereo BioPharma Group1.5651 of 5 stars$2.92+1.7%$7.60+160.3%-58.8%$456.33M$10M-41.7140High Trading VolumeKMDAKamada4.3088 of 5 stars$7.71-2.2%$13.00+68.6%+30.8%$453.14M$167.24M26.59360Positive News Related Companies and Tools Related Companies VALN Alternatives BCAX Alternatives PGEN Alternatives SIGA Alternatives ATYR Alternatives ORKA Alternatives CAPR Alternatives CGEM Alternatives MREO Alternatives KMDA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMRX Stock Alerts